| Identification of markers in lung and breast cancer -> Monitor Keywords |
|
|
  Identification of markers in lung and breast cancerUSPTO Application #: 20060068418Title: Identification of markers in lung and breast cancer Abstract: Methods for identifying expression of markers indicative of the presence of breast cancer and lung cancer are provided. Also provided are articles of manufacture useful in such methods and compositions containing primers and probes useful in such methods. (end of abstract) Agent: Jesse A. Hirshman, Esq. - Pittsburgh, PA, US Inventors: Tony E. Godfrey, Liqiang Xi, Siva Raja, William E. Gooding USPTO Applicaton #: 20060068418 - Class: 435006000 (USPTO) Related Patent Categories: Chemistry: Molecular Biology And Microbiology, Measuring Or Testing Process Involving Enzymes Or Micro-organisms; Composition Or Test Strip Therefore; Processes Of Forming Such Composition Or Test Strip, Involving Nucleic Acid The Patent Description & Claims data below is from USPTO Patent Application 20060068418. Brief Patent Description - Full Patent Description - Patent Application Claims
CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority to U.S. Provisional Patent Application Nos. 60/586,599 and 60/587,019, both filed on Jul. 9, 2004, each of which is incorporated herein by reference in its entirety. BACKGROUND [0002] 1. Field of the Invention [0003] Provided are improved methods for diagnosing cancer cells in lymph nodes, along with compositions and apparatus useful in conducting those methods. [0004] 2. Description of the Related Art [0005] Early detection of cancer typically leads to increased survival rates. Metastatic lesions commonly are detected by histological techniques, including immunohistochemical techniques. Metastasized cells typically infiltrate the lymph nodes, and, thus in most instances, certain sentinel lymph nodes (lymph nodes where metastasized cells typically first infiltrate), or staging lymph nodes (lymph nodes typically analyzed for presence of certain types of cancers), are recognized for each cancer type and are analyzed for the presence of lesions, including micrometastases. Trained histologists often can detect metastatic lesions visually after tissue from a sentinel or staging lymph node is sectioned and stained. Highly trained histologists often can visualize micrometasteses, but the ability to visualize such lesions varies from histologist-to-histologist. [0006] In many surgical procedures to remove tumors, biopsies of sentinel lymph nodes are taken. The surgical procedure is then halted and the excised lymphatic tissue is then analyzed. Once it is determined that the tumor has metastasized, a second, more radical surgical procedure is performed, removing regional lymphatics. A rapid method for identifying tumors is therefore warranted, not only because more assays can be performed in a given time period, thereby increasing laboratory turnaround, but permitting accurate, intraoperative decisions to be made, rather than conducting a second surgical procedure. It is therefore desirable to identify useful diagnostics for malignancies, especially that permit rapid and/or intraoperative detection of lymphatic micrometastases. SUMMARY [0007] The present invention relates to a diagnostic method for detecting the presence of cancer cells in a patient by identifying the expression of certain markers indicative of the presence of cancer cells. [0008] In one embodiment, the present invention relates to a method of identifying the expression of markers indicative of the presence of breast cancer cells in a lymph node of a patient. The method comprises determining if an mRNA species specific to one or more of TACSTD1, CK19, MGB1, MGB2, PIP and CK7 is overabundant in an RNA sample prepared from the lymph node. The overabundance of the mRNA species is indicative of the presence of displaced breast cells in the lymph node. [0009] In another embodiment, the present invention relates to a method for identifying the expression of markers indicative of the presence of lung cancer cells in a lymph node of a patient. The method comprises determining if an mRNA species specific to one or more of CEA, CK7, CK19, PVA, SCCA1.2 (SCCA1+SCCA2), SFTPB and TACSTD1 is overabundant in an RNA sample prepared from the lymph node. The overabundance of the mRNA species is indicative of the presence of displaced lung cells in the lymph node. [0010] In still another embodiment, the present invention relates to an article of manufacture comprising packaging material and one or more nucleic acids specific to one or more of CK7, CK19, MGB1, MGB2, PIP and TACSTD1. The packaging material comprises an indicia, for example and without limitation, a writing, illustration, label, tag, book, booklet and/or package insert, indicating that the one or more nucleic acids can be used in a method of identifying expression of markers indicative of the presence of breast cancer cells in a lymph node of a patient. [0011] In a further embodiment, the present invention relates to an article of manufacture comprising packaging material and one or more nucleic acids specific to one or more of CEA, CK7, CK19, PVA, SCCA1.2, SFTPB and TACSTD1. The packaging material comprises an indicia indicating that the one or more nucleic acids can be used in a method of identifying expression of markers indicative of the presence of lung cancer cells in a lymph node of a patient. [0012] In a still further embodiment, the present invention relates to a composition comprising one or more primers or probes specific to one or more of CK7, CK19, MGB1, MGB2, PIP and TACSTD1 and RNA extracted from the lymph node of a patient diagnosed with or suspected of having breast cancer, or a nucleic acid, or analog thereof, derived from the RNA. [0013] In yet a further embodiment, the present invention relates to a composition comprising one or more primers or probes specific to one or more of CEA, CK7, CK19, PVA, SCCA1.2, SFTPB and TACSTD1 and RNA extracted from the lymph node of a patient diagnosed with or suspected of having lung cancer, or a nucleic acid, or analog thereof, derived from the RNA. BRIEF DESCRIPTION OF THE DRAWINGS [0014] FIG. 1 is a listing of a cDNA sequence of the cytokeratin 7 (CK7) marker (SEQ ID NO: 1). [0015] FIG. 2 is a listing of a cDNA sequence of the cytokeratin 19 (CK19) marker (SEQ ID NO: 2). [0016] FIG. 3 is a listing of a cDNA sequence of the mammaglobin 1 (MGB1) marker (SEQ ID NO: 3). [0017] FIG. 4 is a listing of a cDNA sequence of the mammaglobin 2 (MGB2) marker (SEQ ID NO: 4). [0018] FIG. 5 is a listing of a cDNA sequence of the prolactin-inducible protein (PIP) marker (SEQ ID NO: 5). [0019] FIG. 6 is a listing of a cDNA sequence of the pemphigus vulgaris (PVA) marker (SEQ ID NO: 6). [0020] FIG. 7 is a listing of a cDNA sequence of the squamous cell carcinoma antigen 1 (SCCA1) marker (SEQ ID NO: 7). Continue reading... Full patent description for Identification of markers in lung and breast cancer Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Identification of markers in lung and breast cancer patent application. Patent Applications in related categories: 20080182236 - Asthma susceptibility locus - The present invention describes a susceptibility locus which is functionally related to asthma. The locus maps within human chromosome 7p15-p14. The invention also describes a novel human gene, GPRA. The invention provides diagnostic methods and materials for analysing allelic variation in said locus and the GPRA gene. The invention also ... 20080182237 - Lung cancer-related nucleic acids - Described are polynucleotides associated with lung cancer. The polynucleotides are miRNAs, miRNA precursors, and associated nucleic acids. Methods and compositions are described that can be used for diagnosis, prognosis, and treatment of lung cancer. Also described are methods that can be used to identify modulators of the disease-associated polynucleotides. Also ... ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Identification of markers in lung and breast cancer or other areas of interest. ### Previous Patent Application: Identification of genetic markers associated with parkinson disease Next Patent Application: Immuno polymerase chain reaction assay Industry Class: Chemistry: molecular biology and microbiology ### FreshPatents.com Support Thank you for viewing the Identification of markers in lung and breast cancer patent info. IP-related news and info Results in 0.24311 seconds Other interesting Feshpatents.com categories: Software: Finance , AI , Databases , Development , Document , Navigation , Error |
||
